About Capstone Therapeutics (OTCMKTS:CAPS)
Capstone Therapeutics Corp. is a biotechnology company. The Company is engaged in developing a pipeline of peptides and other molecules aimed at helping patients with under-served medical conditions. The Company entered into a joint venture, LipimetiX Development, Inc., to develop Apo E mimetic peptide molecule AEM-28 and its analogs for the treatment for Homozygous Familial Hypercholesterolemia, Acute Hypertriglyceridemic Pancreatitis, diabetic dyslipidemia and other hyperlipidemic indications. Apolipoprotein E is a 299 amino acid protein that plays a role in lipoprotein metabolism. AEM-28 is a 28 amino acid mimetic of Apo E and AEM-28 and its analogs, including AEM-28-14, a 28 amino acid mimetic of Apo E (with an aminohexanoic acid group and a phospholipid), and both contain a domain that anchors into a lipoprotein surface while also providing the Apo E receptor binding domain, which allows clearance through the heparan sulfate proteoglycan receptors (Syndecan-1) in the liver.
Industry, Sector and Symbol
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value($0.02) per share
Price / Book-2.50
Return on EquityN/A
Return on Assets-135.17%
Capstone Therapeutics (OTCMKTS:CAPS) Frequently Asked Questions
What is Capstone Therapeutics' stock symbol?
Capstone Therapeutics trades on the OTCMKTS under the ticker symbol "CAPS."
How were Capstone Therapeutics' earnings last quarter?
Capstone Therapeutics Corp (OTCMKTS:CAPS) released its quarterly earnings results on Monday, August, 14th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter. View Capstone Therapeutics' Earnings History.
When will Capstone Therapeutics make its next earnings announcement?
Who are some of Capstone Therapeutics' key competitors?
Some companies that are related to Capstone Therapeutics include Strata Skin Sciences (SSKN), Amedica (AMDA), Orexigen Therapeutics (OREX), Dextera Surgical (DXTR), TearLab (TEAR), Rosetta Genomics (ROSG), Lombard Medical Technologies (EVARF), Avinger (AVGR), BG Medicine (BGMD), Tetralogic Pharmaceuticals (TLOG), Affymax (AFFY), Callitas Health In (MPHMF), Imaging Canada Liquidating (IMRSQ), Echo Therapeutics (ECTE) and Patheon (PTHN).
Who are Capstone Therapeutics' key executives?
Capstone Therapeutics' management team includes the folowing people:
- John M. Holliman III, Executive Chairman of the Board, Principal Executive Officer (Age 61)
- Leslie M. Taeger, Chief Financial Officer, Senior Vice President, Principal Financial and Accounting Officer (Age 65)
- Randolph C. Steer MD. Ph.D., Consultant (Age 67)
- Fredric J. Feldman Ph.D., Director (Age 76)
- Matthew E. Lipman, Director
- Michael E. Toporek, Director
- Elwood D. Howse Jr., Independent Director (Age 75)
Has Capstone Therapeutics been receiving favorable news coverage?
News coverage about CAPS stock has trended somewhat positive this week, according to Accern. The research group identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Capstone Therapeutics earned a coverage optimism score of 0.08 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 45.98 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
How do I buy shares of Capstone Therapeutics?
Shares of CAPS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Capstone Therapeutics' stock price today?
One share of CAPS stock can currently be purchased for approximately $0.05.
How big of a company is Capstone Therapeutics?
Capstone Therapeutics has a market capitalization of $2.72 million. Capstone Therapeutics employs 2 workers across the globe.
How can I contact Capstone Therapeutics?
Capstone Therapeutics' mailing address is 1275 W. Washington Street Suite 104, Tempe AZ, 85281. The biotechnology company can be reached via phone at 602-286-5520 or via email at [email protected]
MarketBeat Community Rating for Capstone Therapeutics (CAPS)MarketBeat's community ratings are surveys of what our community members think about Capstone Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Capstone Therapeutics (OTCMKTS:CAPS) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Capstone Therapeutics (OTCMKTS:CAPS) Earnings History and Estimates Chart
Capstone Therapeutics (OTCMKTS CAPS) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/26/2018|| || || || || || || || |
Capstone Therapeutics (OTCMKTS:CAPS) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Capstone Therapeutics (OTCMKTS:CAPS)
No dividend announcements for this company have been tracked by MarketBeat.com
Capstone Therapeutics (OTCMKTS CAPS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 9.40%
Capstone Therapeutics (OTCMKTS CAPS) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|10/5/2017||Lloyd I Miller III||Major Shareholder||Sell||100,000||$0.06||$6,000.00|| |
|7/14/2017||Value Fund L P Biotechnology||Insider||Sell||4,341,586||$0.06||$260,495.16|| |
|1/4/2017||Leslie M Taeger||CFO||Buy||50,000||$0.07||$3,500.00||94,574|| |
|12/16/2016||Lloyd I. Miller III||Major Shareholder||Sell||38,967||$0.04||$1,558.68|| |
|12/15/2016||Lloyd I Miller III||Major Shareholder||Sell||20,000||$0.04||$800.00||38,967|| |
|8/12/2016||Lloyd I Miller III||Major Shareholder||Sell||16,000||$0.06||$960.00||58,967|| |
|8/1/2016||Lloyd I Miller III||Major Shareholder||Sell||80,000||$0.06||$4,800.00||58,967|| |
|6/8/2016||Lloyd I Miller III||Major Shareholder||Sell||14,000||$0.08||$1,120.00||58,967|| |
|12/6/2013||John M Holliman III||Chairman||Buy||25,000||$0.26||$6,500.00|| |
|8/7/2013||Lloyd I Miller III||Major Shareholder||Buy||87,500||$0.23||$20,125.00|| |
|7/30/2013||Lloyd I Miller III||Major Shareholder||Buy||1,139,000||$0.20||$227,800.00|| |
|6/10/2013||Lloyd I Miller III||Major Shareholder||Buy||300,000||$0.18||$54,000.00|| |
|4/8/2013||Fredric J Feldman||Director||Buy||25,000||$0.21||$5,250.00|| |
|12/17/2012||Lloyd I Miller III||Major Shareholder||Buy||175,000||$0.16||$28,000.00|| |
|12/6/2012||Lloyd I Miller III||Major Shareholder||Buy||19,750||$0.16||$3,160.00|| |
|10/19/2012||John M Holliman III||Chairman||Buy||150,000||$0.14||$21,000.00|| |
|9/19/2012||Lloyd I Miller III||Major Shareholder||Buy||261,183||$0.16||$41,789.28|| |
|8/28/2012||Lloyd I Miller III||Major Shareholder||Buy||938,064||$0.16||$150,090.24|| |
Capstone Therapeutics (OTCMKTS CAPS) News Headlines
Capstone Therapeutics (OTCMKTS:CAPS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Capstone Therapeutics (OTCMKTS:CAPS) Income Statement, Balance Sheet and Cash Flow Statement
Capstone Therapeutics (OTCMKTS CAPS) Stock Chart for Saturday, March, 24, 2018